Literature DB >> 28100646

Targeting the correct target in HCC.

Carmen Berasain1,2,3, André Lechel4.   

Abstract

Keywords:  HEPATITIS B; HEPATOCELLULAR CARCINOMA

Mesh：

Year:  2017        PMID： 28100646     DOI： 10.1136/gutjnl-2016-313462

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  4 in total

1.  Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.

Authors:  Gundula Streubel; Sabine Schrepfer; Hannah Kallus; Ulrike Parnitzke; Tanja Wulff; Frank Hermann; Matthias Borgmann; Svetlana Hamm
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

2.  EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma.

Authors:  Hsin-Yi Lee; Chi-Kuan Chen; Chun-Ming Ho; Szu-Shuo Lee; Chieh-Yu Chang; Kuan-Ju Chen; Yuh-Shan Jou
Journal:  Oncotarget       Date:  2018-01-11

3.  BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.

Authors:  Weiya Cao; Xueke Liu; Yinci Zhang; Amin Li; Yinghai Xie; Shuping Zhou; Li Song; Ruyue Xu; Yongfang Ma; Shiyu Cai; Xiaolong Tang
Journal:  Biomed Res Int       Date:  2021-04-16       Impact factor: 3.411

4.  Type-I-IFN-Stimulated Gene TRIM5γ Inhibits HBV Replication by Promoting HBx Degradation.

Authors:  Guangyun Tan; Zhaohong Yi; Hongxiao Song; Fengchao Xu; Feng Li; Roghiyh Aliyari; Hong Zhang; Peishuang Du; Yanhua Ding; Junqi Niu; Xiaosong Wang; Lishan Su; F Xiao-Feng Qin; Genhong Cheng
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.